The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer

#2958

Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.

Aim(s): Evaluate the NETest, a blood-based neuroendocrine multigenomic biomarker, as a CRPC diagnostic.

Materials and methods: Prostate cancers (PCA): CRPC (50), hormone-sensitive PCAs (115), and benign prostatic hyperplasia (BPH) (41). NETest assay: PCR: NETest score 0-100, cut-off 40 for progressive disease. PSA ECLIA assay: cut-off 4ng/L, >10ng/ml=critical value. ANOVA, AUROC analyses and sensitivity/specificity metrics. Data is mean ± SEM.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Modlin I

Authors: Modlin I, Kidd M, Rahbar K, Malczewska A, Rajwa P,

Keywords: Biomarker, NETest, PSA, prostate cancer, neuroendocrine phenotype, castration-resistance, neuroendocrine,